Skip to main content
. 2020 Dec 3;12(4):444–452. doi: 10.1111/1759-7714.13763

Figure 4.

Figure 4

Progression‐free survival (PFS) of all patients (a) and comparisons of survival according to Group A (EGFR mutation only in ctDNA) versus Group B (EGFR mutation in ctDNA and tumor DNA) (b); final dose of afatinib (c); and type of EGFR mutation (d). EGFRm, epidermal growth factor receptor mutation; ctDNA, circulating tumor DNA